In January, the Generics and Biosimilars Initiative (GaBI) published a whitepaper entitled “Medicare Drug Price Negotiations: Impact on Healthcare Development and Patient Access to Medicines”. The paper’s content is drawn from a webinar on the same topic hosted by ASBM and GaBI on July 26, 2023. It examines the likely negative effects of IRA’s price negotiation provisions, which allow the Centers for Medicare and Medicaid Services to negotiate prices of certain costly drugs, including many biologic medicines.
The paper’s authors include three former government officials who worked on the development and implementation of Medicare Part D, the prescription drug benefit being modified by the IRA’s new price-setting provisions; as well as a prominent patient advocacy leader:
- Michael S Reilly, Esq; Executive Director, ASBM
- Thomas R Barker, Esq; Former Acting General Counsel of the US Department of Health and Human Services; Former Commissioner of the Medicaid and CHIP Payment and Access Commission (MACPAC)
- Charles Clapton, Vice President, Federal Government Affairs, Gilead Sciences
- Andrew Spiegel, Esq; Executive Director, Global Colon Cancer Association
The paper may be read online here; it will also be available in the print edition of GaBI Journal.
